Back to News
Market Impact: 0.4
FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Eli Lilly announced FDA approval of an expanded indication for Jaypirca (pirtobrutinib) for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The approval broadens Jaypirca's eligible patient population and supports Lilly's oncology growth opportunity.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.60
Ticker Sentiment
LLY0.80
More News
- Wall Street Is Bracing for the Fed's Next Move on Rates. These 3 Stocks Win Either Way.
- Trump taps Director of National Intelligence Jay Clayton as AI czar: WSJ reports
- Tesla’s Cybercab had a rocky first month in Austin. Now comes the hard part: expanding
- Trump teases more inflationary money for voters ahead of midterm elections, now promising $90 payments after touting $500 and $5,000 checks
- Sports betting is America’s new pastime—and it’s bigger than movies, music, and museums together as Americans wage a whopping $166 billion on bets
- Amazon responds to data center backlash, says it no longer uses NDAs